Payment overview · 2025
General Payments
$57.28
3 reported records · 3 companies
Healthcare provider profile · identity verified
Stephen Day Hoag, MD
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, NY · NPI 1740254242
Verified facts
What the public records show
CMS Open Payments records show Stephen Day Hoag, MD received $57.28 in general payments during 2025 across 3 reported records.
Astellas Pharma US Inc accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.08 | 40.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.54 | 34.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.66 | 25.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $57.28 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 144 |
| Lisinopril | Lisinopril | 168 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 54 |
| Gabapentin | Gabapentin | 136 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 44 |
| Losartan Potassium | Losartan Potassium | 120 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 32 |
| Omeprazole | Omeprazole | 104 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 26 |
| Famotidine | Famotidine | 95 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 91 | 17 |
| Metformin Hcl Er | Metformin Hcl | 90 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Pregabalin | Pregabalin | 84 | 21 |
| Furosemide | Furosemide | 82 | 25 |
| Jardiance | Empagliflozin | 80 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 16 |
| Simvastatin | Simvastatin | 73 | 18 |
| Meloxicam | Meloxicam | 71 | 17 |
| Sertraline Hcl | Sertraline Hcl | 71 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 17 |
| Trulicity | Dulaglutide | 54 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 18 |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Metformin Hcl | Metformin Hcl | 50 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 11 |
| Trazodone Hcl | Trazodone Hcl | 49 | 17 |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 14 |
| Spironolactone | Spironolactone | 42 | 14 |
| Allopurinol | Allopurinol | 41 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Alprazolam | Alprazolam | 30 | 13 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ozempic | Semaglutide | 29 | 12 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levocarnitine | Levocarnitine | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57.28 · 3 records | Astellas Pharma US Inc | OTEZLA, REPATHA, TRELEGY ELLIPTA, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error